Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 4/20 | 0.40 |
| ▸ | NOS3 | P29474 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473665 | 0.80 | NOS3 (0.39) | ALDH1A1TLR8NOS2NOS3CA12 | |
| SCHEMBL9984313 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2HPGDALDH1A1TLR8NOS2 | |
| SCHEMBL22224597 | 0.77 | HPGD (0.46) | SMN1; SMN2HPGDALDH1A1TLR8NOS2 | |
| SCHEMBL21747948 | 0.76 | TLR8 (0.40) | TLR8NOS2NOS3MEN1POLB | |
| SCHEMBL1002382 | 0.72 | LTA4H (0.59) | SMN1; SMN2HPGDALDH1A1TLR8NOS2 | |
| SCHEMBL11816464 | 0.72 | IKBKB (0.46) | SMN1; SMN2HPGDALDH1A1MAPTHSD17B10 | |
| SCHEMBL28427215 | 0.70 | ALDH1A1 (0.52) | ALDH1A1KDM4EMAPTMEN1POLB | |
| SCHEMBL31007081 | 0.69 | MET (0.39) | CDK2 | |
| SCHEMBL28282683 | 0.69 | SMN1; SMN2 (0.39) | SMN1; SMN2HPGDALDH1A1TLR8KDM4E | |
| SCHEMBL28282695 | 0.69 | NOS2 (0.50) | SMN1; SMN2HPGDALDH1A1TLR8NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370440-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-24 | — | — | US | disclosed |
| EP-3807274-B1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-07-27 | — | — | EP | disclosed |
| EP-3807274-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | Lead Discovery Center GmbH (DE) | 2021-04-21 | — | — | EP | disclosed |
| CN-112585138-A | 4-substituted pyrrolo [2,3-b ] pyridines as ErbB modulators useful in the treatment of cancer | 利德探索中心有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020039060-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2020-02-27 | — | — | WO | disclosed |
| EP-3613738-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | Lead Discovery Center GmbH (DE) | 2020-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370440-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | ERBB2, ERBB4, ERBB3 | SMN1; SMN2 4413/4885HPGD 683/4885ALDH1A1 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.